PMVP Stock Price, PMV Pharmaceuticals, . Quote, Chart

Market Summary

USD2.130.00

Market Closed

0.00%

PMVP Alerts

JPMORGAN CHASE & CO reported owning 0% of PMVP [2024-04-09]

PMVP Stock Price

View Fullscreen

PMVP RSI Chart

PMVP Valuation

Market Cap

109.6M

Price/Earnings (Trailing)

-1.68

EV/EBITDA

-1.19

Price/Free Cashflow

-1.88

MarketCap/EBT

-1.68

PMVP Price/Earnings (Trailing)

PMVP Profitability

Return on Equity

-30.61%

Return on Assets

-27.48%

Free Cashflow Yield

-53.14%

PMVP Fundamentals

PMVP Earnings

Earnings (TTM)

-65.1M

Earnings Growth (Yr)

20.17%

Earnings Growth (Qtr)

3.08%

Breaking Down PMVP Revenue

Last 7 days

1.0%

Last 30 days

18.4%

Last 90 days

39.5%

Trailing 12 Months

-62.8%

How does PMVP drawdown profile look like?

PMVP Financial Health

Current Ratio

16.79

PMVP Investor Care

Shares Dilution (1Y)

12.38%

Diluted EPS (TTM)

-1.33

Tracking the Latest Insider Buys and Sells of PMV Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 18, 2024	carulli michael	acquired	-	-	82,220	chief financial officer
Jan 18, 2024	jalota deepika	acquired	-	-	95,555	chief development officer
Jan 18, 2024	mack david henry	acquired	-	-	163,890	president and ceo
Nov 22, 2023	orbimed advisors llc	sold	-195,763	2.23	-87,786	-
Nov 10, 2023	mack david henry	gifted	-	-	85,307	president and ceo
Nov 10, 2023	mack david henry	gifted	-	-	-85,307	president and ceo
Oct 18, 2023	mack david henry	acquired	105,156	0.53	198,407	president and ceo
Sep 15, 2023	jalota deepika	sold	-27,168	6.62	-4,104	chief development officer
Sep 15, 2023	alland leila	sold	-41,646	6.62	-6,291	chief medical officer
Aug 07, 2023	mack david henry	acquired	45,315	0.53	85,500	president and ceo

Which funds bought or sold PMVP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 13, 2024	FMR LLC	added	9.11	-2,884	4,296	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	4.97	-1,131,820	1,535,500	-%
May 13, 2024	PERSONAL CFO SOLUTIONS, LLC	unchanged	-	-770,479	935,581	0.15%
May 13, 2024	Nuveen Asset Management, LLC	unchanged	-	-214,143	260,031	-%
May 13, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	5.47	-25,055	34,369	-%
May 13, 2024	XTX Topco Ltd	reduced	-21.81	-441,667	331,510	0.04%
May 13, 2024	UBS Group AG	added	4.5	-169,230	227,161	-%
May 13, 2024	Ameritas Investment Partners, Inc.	unchanged	-	-5,281	6,412	-%
May 10, 2024	Acuitas Investments, LLC	new	-	598,188	598,188	0.30%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	reduced	-51.05	-1,264,400	463,861	-%

Are Funds Buying or Selling PMVP?

Are funds buying PMVP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PMVP

No. of Funds

PMVP Alerts

JPMORGAN CHASE & CO reported owning 0% of PMVP [2024-04-09]

Unveiling PMV Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	jpmorgan chase & co	0.0%	15,573	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	0%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2024	arrowmark colorado holdings llc	5.31%	2,714,143	SC 13G
Feb 14, 2024	boxer capital, llc	0%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	2.2%	6	SC 13G/A
Feb 13, 2024	vanguard group inc	4.70%	2,405,307	SC 13G/A
Jan 29, 2024	blackrock inc.	6.3%	3,229,797	SC 13G/A
Jan 23, 2024	state street corp	1.41%	723,454	SC 13G/A
Jan 23, 2024	jpmorgan chase & co	7.1%	3,674,814	SC 13G/A

Recent SEC filings of PMV Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 24, 2024	DEFA14A	DEFA14A
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	ARS	ARS
Apr 09, 2024	SC 13G/A	Major Ownership Report
Feb 29, 2024	8-K	Current Report
Feb 29, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to PMV Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.2B	6.8B	19.54%	-2.80%	-8.24	7.18	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	0.98%	-26.98%	-56.37	9.34	75.20%	68.82%
BMRN	15.1B	2.5B	-12.72%	-14.31%	73.61	6.12	13.74%	186.89%
INCY	12.8B	3.8B	6.98%	-11.75%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	6.22%	110.41%	-9.93	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-16.95%	-51.10%	-11.99	9.55	394.93%	39.61%
AXSM	3.7B	251.0M	9.36%	-4.29%	-12.4	14.64	73.58%	-86.73%
ARWR	2.8B	240.7M	-10.69%	-43.90%	-6.04	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.91	4.73	60.38%	-34.49%
NVAX	1.9B	996.6M	206.31%	55.15%	-4.75	1.9	-26.66%	65.49%
CRBP	456.3M	881.7K	5.07%	336.18%	-13.52	481.06	-77.61%	33.36%
INO	297.2M	4.9M	3.08%	29.79%	-2.38	61.07	-54.97%	48.23%
IBIO	16.2M	2.1M	-10.40%	79.21%	-0.7	7.61	-13.45%	69.54%

PMV Pharmaceuticals, Inc. News

Latest updates

PMV Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-6.1%	237	252	261	242	254	270	285	301	315	332	344	356	354	366	374	103
Current Assets	-2.4%	202	207	205	190	233	247	265	282	288	301	314	323	335	365	374	102
Cash Equivalents	26.4%	48.00	38.00	52.00	68.00	143	108	100	87.00	116	172	177	189	209	361	373	73.00
Net PPE	2.2%	11.00	11.00	11.00	11.00	11.00	11.00	10.00	9.00	5.00	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-8.6%	24.00	26.00	23.00	24.00	24.00	24.00	24.00	24.00	23.00	23.00	19.00	18.00	6.00	6.00	5.00	5.00
Current Liabilities	-14.0%	12.00	14.00	11.00	11.00	11.00	11.00	12.00	11.00	12.00	12.00	9.00	8.00	6.00	6.00	5.00	5.00
Shareholder's Equity	-5.8%	213	226	238	218	230	246	261	277	292	309	325	338	348	359	369	-
Retained Earnings	-4.9%	-325	-310	-294	-277	-260	-241	-221	-203	-186	-167	-149	-134	-121	-109	-99.43	-75.44
Additional Paid-In Capital	0.5%	538	535	532	496	490	488	484	481	479	476	474	472	470	469	468	5.00
Shares Outstanding	0%	51.00	51.00	51.00	46.00	46.00	46.00	46.00	46.00	45.00	45.00	45.00	45.00	-	-	-	-
Float	-	-	-	-	209	-	-	-	543	-	-	-	1,229	-	1,920	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-33.9%	-16,184	-12,085	-15,659	-12,901	-15,012	-15,324	-16,759	-13,679	-17,998	-12,028	-12,398	-9,241	-12,904	-10,312	-7,393	-6,896	-8,138	-	-	-
Share Based Compensation	-12.0%	2,610	2,966	3,324	3,153	2,932	3,052	2,448	2,518	2,177	1,767	1,796	1,150	627	584	670	383	296	-	-	-
Cashflow From Investing	1111.1%	26,166	-2,588	-33,639	-63,963	49,645	23,223	29,513	-15,279	-38,825	7,559	-693	-10,553	-139,897	-57.00	8,037	26,315	-6,384	-	-	-
Cashflow From Financing	-100.0%	-	288	33,146	2,131	12.00	548	6.00	276	128	295	309	1,256	162	-1,359	294,455	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PMVP Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 13,186	$ 15,073
General and administrative	5,035	6,407
Total operating expenses	18,221	21,480
Loss from operations	(18,221)	(21,480)
Other income (expense):
Interest income, net	2,952	2,325
Other income (expense), net	(1)	27
Total other income (expense)	2,951	2,352
Loss before provision for income taxes	(15,270)	(19,128)
Net loss	(15,270)	(19,128)
Unrealized (loss) gain on available for sale investments, net of tax	(319)	329
Foreign currency translation loss	(34)
Total other comprehensive (loss) income	(353)	329
Total comprehensive loss	$ (15,623)	$ (18,799)
Net loss per share - basic	$ (0.3)	$ (0.42)
Net loss per share - diluted	$ (0.3)	$ (0.42)
Weighted-average common shares outstanding - basic	51,445,862	45,773,357
Weighted-average common shares outstanding - diluted	51,445,862	45,773,357

PMVP Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 47,654	$ 37,706
Restricted cash	822	822
Marketable securities, current	150,285	165,351
Prepaid expenses and other current assets	3,699	3,530
Total current assets	202,460	207,409
Property and equipment, net	10,903	10,666
Marketable securities, noncurrent	15,120	25,505
Right-of-use assets	8,211	8,382
Other assets	182	190
Total assets	236,876	252,152
Current liabilities:
Accounts payable	859	3,237
Accrued expenses	10,319	9,940
Operating lease liabilities, current	880	852
Total current liabilities	12,058	14,029
Operating lease liabilities, noncurrent	12,142	12,434
Total liabilities	24,200	26,463
Stockholders’ equity:
Preferred stock, $0.00001 par value, 5,000,000 shares authorized at March 31, 2024 and December 31, 2023. No shares issued or outstanding at March 31, 2024 and December 31, 2023.
Common stock, $0.00001 par value, 1,000,000,000 shares authorized; 51,445,862 and 51,445,862 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.
Additional paid-in capital	538,078	535,468
Accumulated deficit	(325,273)	(310,003)
Accumulated other comprehensive (loss) income	(129)	224
Total stockholders’ equity	212,676	225,689
Total liabilities and stockholders’ equity	$ 236,876	$ 252,152

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

CEO	Dr. David H. Mack Ph.D.
WEBSITE	pmvpharma.com
INDUSTRY	Biotechnology
EMPLOYEES	62

PMV Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for PMV Pharmaceuticals, Inc.? What does PMVP stand for in stocks?

PMVP is the stock ticker symbol of PMV Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PMV Pharmaceuticals, Inc. (PMVP)?

As of Mon May 13 2024, market cap of PMV Pharmaceuticals, Inc. is 109.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PMVP stock?

You can check PMVP's fair value in chart for subscribers.

What is the fair value of PMVP stock?

You can check PMVP's fair value in chart for subscribers. The fair value of PMV Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PMV Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PMVP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PMV Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether PMVP is over valued or under valued. Whether PMV Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact PMV Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PMVP.